A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT07520357
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Advanced Neuroendocrine Carcinoma
Interventions
DRUG:
SHR-A1904 Injection
Sponsor
Beijing GoBroad Hospital